BiotechTube

Placebo + KHK4827

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

Nov 1, 2011 → Sep 1, 2012

NCT ID
NCT01488201

About Placebo + KHK4827

Placebo + KHK4827 is a phase 1 stage product being developed by Kyowa Kirin for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01488201. Target conditions include Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Psoriasis were approved

Approved (20) Terminated (3) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Ilumya Injectable ProductSun PharmaceuticalApproved
✅TildrakizumabSun PharmaceuticalApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01488201Phase 1Completed

Competing Products

20 competing products in Psoriasis

See all competitors
ProductCompanyStageHype Score
PPC-06 400 mg QD + PPC-06 400 mg BID + PPC-06 600 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
XP23829 400 mg QD + XP 23829 800 mg QD + XP23829 400 mg BID + PlaceboDr. Reddy's LaboratoriesPhase 2
32
Ixekizumab + PlaceboEli LillyPhase 2
35
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
21
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
27
IxekizumabEli LillyPhase 3
40
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
40
Placebo + BaricitinibEli LillyPhase 2
35
CT-P43 + StelaraCelltrionPhase 3
40
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
AMG 139AstraZenecaPhase 1
29
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 2
35
Tacrolimus CreamAstellas PharmaPhase 3
40
alefaceptAstellas PharmaPhase 3
40
peficitinib + PlaceboAstellas PharmaPhase 2
35
AlefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40